Search - tctmd.com

Displaying 61 - 80 of 95

Sort: Relevancy | Date

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Neal S. Kleiman

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Presenter: C. Michael Gibson, Marco Valgimigli, Guido Parodi

October 11, 2015

Presentation

Comparison of Ticagrelor vs Prasugrel to Prevent Periprocedural Myonecrosis in ACS

Presenter: Laurent Bonello

June 03, 2015

Presentation

Ticagrelor vs Clopidogrel in Troponin-Negative ACS Patients Undergoing Ad Hoc PCI

Presenter: Roxana Mehran

May 08, 2015

Presentation ACC 2015

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Presenter: Marc S. Sabatine

March 14, 2015

Presentation

Economic Analysis of Ticagrelor TherapyFrom a US Perspective

Presenter: Patricia A. Cowper

February 02, 2015

Presentation TCT 2014

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

Presenter: Dirk Sibbing

September 14, 2014

Presentation TCT 2014

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Matthew J. Price

September 14, 2014

Presentation

Ticagrelor vs Clopidogrel in Patients with NSTE-ACS With or Without Revascularization

Presenter: D. Lindholm

April 25, 2014

Presentation

The Efficacy of Ticagrelor Is Maintained in Women with ACS Participating in the PLATO trial

Presenter: Steen Husted

April 16, 2014

Presentation

Loading Dose Has No Additive Effect on Platelet Aggregation During the Switch from Ongoing Clopidogrel to Ticagrelor in ACS Patients

Presenter: G. Caiazzo

January 28, 2014

Presentation TCT 2013

Mortality Trumps All: Ticagrelor for (Nearly) All!

Presenter: Michel Le May

October 31, 2013

Presentation TCT 2013

Emerging Ticagrelor Data: Insights Into its Safety and Efficacy Profile

Presenter: Dimitrios Alexopoulos

October 31, 2013

Presentation TCT 2013

Pre-load wtih Platelet ADP Receptor Inhibition in STEMI: Prasugrel, Ticagrelor, Clopidogrel, Or Does it Matter?

Presenter: Michel Le May

October 30, 2013

Presentation TCT 2013

No! Aspirin and Ticagrelor Is a Much Better Option

Presenter: Emmanouil Brilakis

October 28, 2013

Presentation

Stent Thrombosis with Ticagrelor vs. Clopidogrel in Patients with Acute Coronary Syndromes

Presenter: Philippe Gabriel Steg

August 02, 2013

Presentation SOLACI 2013

Prasugrel e Ticagrelor: Agentes de Primeira Opção para Todos Os Pacientes Com Síndrome Coronária Aguda?

Presenter: Carlos V. Serrano Jr.

July 26, 2013

Presentation

Comparison of Prasugrel and Ticagrelor Loading Doses in STEMI Patients

Presenter: Guido Parodi

April 04, 2013

Presentation TCT 2013

Effect of Ticagrelor on the Outcomes of Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From The PLATelet inhibition and patient Outcomes (PLATO) trial

Presenter: Emmanouil Brilakis, Claes Held, Bernhard Meier, Frank Cools, Marc Claeys, Jan Cornel, Philip Aylward, Basil Lewis, Douglas Weaver, Gunnar Brandrup- Wognsen, Susanna Stevens, Lars Wallentin, Stefan James

January 31, 2013

Presentation TCT 2013

Double (360mg) Loading Dose Of Ticagrelor In Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Presenter: Dimitrios Alexopoulos, Ioanna Xanthopoulou, Vassilios Gkizas, George Kassimis, Konstantinos Theodoropoulos, Tsigkas Grigorios, Ioannis Chiladakis, Anastasia Damelou, George Hahalis, Periklis Davlouros

January 31, 2013

Advertisement

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Comparison of Ticagrelor vs Prasugrel to Prevent Periprocedural Myonecrosis in ACS

Ticagrelor vs Clopidogrel in Troponin-Negative ACS Patients Undergoing Ad Hoc PCI

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Economic Analysis of Ticagrelor TherapyFrom a US Perspective

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Ticagrelor vs Clopidogrel in Patients with NSTE-ACS With or Without Revascularization

The Efficacy of Ticagrelor Is Maintained in Women with ACS Participating in the PLATO trial

Loading Dose Has No Additive Effect on Platelet Aggregation During the Switch from Ongoing Clopidogrel to Ticagrelor in ACS Patients

Mortality Trumps All: Ticagrelor for (Nearly) All!

Emerging Ticagrelor Data: Insights Into its Safety and Efficacy Profile

Pre-load wtih Platelet ADP Receptor Inhibition in STEMI: Prasugrel, Ticagrelor, Clopidogrel, Or Does it Matter?

No! Aspirin and Ticagrelor Is a Much Better Option

Stent Thrombosis with Ticagrelor vs. Clopidogrel in Patients with Acute Coronary Syndromes

Prasugrel e Ticagrelor: Agentes de Primeira Opção para Todos Os Pacientes Com Síndrome Coronária Aguda?

Comparison of Prasugrel and Ticagrelor Loading Doses in STEMI Patients

Effect of Ticagrelor on the Outcomes of Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From The PLATelet inhibition and patient Outcomes (PLATO) trial

Double (360mg) Loading Dose Of Ticagrelor In Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content